

BIOGRAPHY

Dr. Razvan Andrei Popescu has trained in Internal Medicine, Medical Oncology and Hematology, obtaining specializations in Switzerland and the UK, following his graduation in 1989, a Doctorate in Medicine from the University of Basel in 1990 and a post-graduate Molecular Oncology fellowship in Canada (1990-1992). He became a Member of the Royal College of Physicians (MRCP) of London following the MRCP examination in 1996. Dr. Popescu founded and is Head of Medical Oncology and Co-Chair of the Tumor Center Aarau and heads Medical Oncology at the Hirslanden Clinic in Aarau, Switzerland.

He is particularly interested in and has extensive clinical experience in gastro-intestinal, breast, gynecologic and uro-genital cancers, supportive/ palliative care and treatment of elderly patients with cancer. He received formal training in palliative care (palliative care clinics and courses) as part of his UK Oncology training. He has been Co-President of palliative-aargau (www.palliative-aargau.ch), the Palliative Care Society of Kanton Aargau, Switzerland since 2013 and actively promotes early integration of Oncology and Palliative Care. The Tumor Zentrum Aarau was recognized as the second European Society of Medical Oncology (ESMO) Designated Center of Integrated Oncology and Palliative Care in German-speaking Switzerland in 2013. He is an active member of MASCC.

He has contributed to the design of clinical trials in Hodgkin's disease, breast, colorectal, esophageal, bladder cancer and melanoma, and participated in the first ASCO –AACR –FECS Workshop on Methods in Clinical Cancer Research in Flims. He was a co-founder of the Flims Alumni Club (FAC), the interdisciplinary European association of young oncologists and researchers, focused among other goals on clinical trial methodology. Dr. Popescu served as the Flims Alumni Club's first Treasurer and was its President 2003-2007.

Dr Popescu has helped organize symposia within ESMO, ESTRO, EACR and ECCO congresses, has contributed to various ESMO activities as a Faculty Member (among others for clinical trial design, Geriatric Oncology, Supportive and Palliative Care, Oncopolicy etc.) and has served as Deputy Director or Scientific Coordinator for the European School of Oncology (ESO) Masterclasses in Clinical Oncology from 2004 to 2020. He is part of the ESO core faculty in GI cancers, Breast cancer, Elderly, Supportive and Palliative Care, has served as visiting professor for ESO in various occasions and is a Senior Faculty Member of the College of the European School of Oncology (ESCO). Dr Popescu is currently developing a Training Programme for Cancer Professionals for the ESO College "Improving the Outcome for Cancer Patients in Europe" set to start in 2022, which he will co-chair with Prof Peter Selby.

His Romanian origin has enabled him to establish close links to and friendships with colleagues in Central and Eastern Europe, and he has participated in a range of educational activities and congresses in this part of Europe. He is actively collaborating in efforts to improve structure of oncology in Central and Eastern Europe and has published on hurdles to access cancer medicine in these countries. From 2010 to 2013 he was the Coordinator of the ESO Eastern European and Balkan Program and initiated and chaired the first 3 Eastern European and Balkan Masterclasses in Clinical Oncology from 2011 to 2013. He is a Visiting Professor in the Faculty of Medicine, University of Belgrade, Serbia.

Dr. Razvan Popescu has served ESMO (the European Society of Medical Oncology) as a member of the Young Oncologists Committee 2003-2007, member of the Fellowship and Awards Committee 2006-2010, Chair of ESMO Membership Committee and Member of ESMO Board of Directors 2008-2010. From 2010 to 2014 he chaired the joined ESMO National Representatives and Membership Committee and was a Member of the ESMO Executive Committee. He was lead author of the ESMO Position Paper on Medical Oncology published in 2014 and co-author of a paper on personalized cancer medicine.

He is member of the ASCO Educational Committee and chaired the Global Health Educational Track for ASCO 2020. He was one of the 4 Europeans serving on ASCOs International Affairs Committee 2017-2020 and has been a member of the ASCO Quality Training Program Steering Group since 2020.

CURRICULUM VITAE

Personal details

Name: Razvan Andrei Popescu

Address (work): Tumor Center Aargau
Hirslanden Clinic Aarau
Rain 34
5001 Aarau
Switzerland
Telephone ++41 62 836 7830
Fax ++41 62 836 7831
Mobile ++41 78 797 6200
Email: Razvan.Popescu@hirslanden.ch

Place and date of birth: Bucharest, Romania, 31.7.1964

Parents: Horia Popescu MD, PhD
Ioana Lancranjan-Popescu, MD, PhD

Citizenship: Swiss

Languages: English, German, French, Romanian, Italian, Spanish

Current Appointment

Co-Chair Tumor Center Aargau and Head of Medical Oncology, Hirslanden Clinic Aarau, Switzerland since 2004

Examinations and Qualifications

2000: Specialist in Medical Oncology (UK, European Union)

2000: European Society of Medical Oncology Certification Examination

1998: Specialist in Medical Oncology / Hematology (Switzerland)

1996: Specialist in Internal Medicine (Switzerland)

1996: Membership of the Royal College of Physicians (UK)

1990: Medical Doctorate, Faculty of Medicine, University of Basle

1989: FMGEMS (US medical examination)

1989: Swiss Staatsexamen (final Swiss medical examination)

Professional Memberships

American Society of Clinical Oncology (ASCO)

- Member International Affairs Committee 2017-2020
- Member Educational Committee 2018-2021, Chair Global Health Track ASCO 2020
- Member ASCO Quality Training Program Steering group

European Society of Medical Oncologists (ESMO)

- Member of Young Oncologists Committee 2003-2007
- Member of Fellowship and Awards Committee 2006-2010
- Chair ESMO Membership Committee and Member of ESMO Board of Directors 2008-2010
- Chair ESMO National Representatives and Membership Committee 2010 – 2014
- Member ESMO Executive Committee 2010 – 2014

European School of Oncology (ESO)

- Core Faculty Member
- Deputy Director/ Scientific Coordinator of ESO-ESMO Masterclasses in Clinical Oncology (2004-2020)
- Coordinator ESO Eastern Europe and Balkan Region Program 2010-2013
- Founder and Chair of Eastern Europe and Balkan Region (EEBR) Masterclass in Clinical Oncology 2011 – 2013
- Teaching at Masterclasses and visiting professorships since 2004.
- Currently developing with Prof Peter Selby a Training Program for Cancer Professionals for ESO (together with ECCO and SPCC) "Improving the Outcome for Cancer Patients in Europe"

Flims Alumni Club

- Treasurer 2000- 2003
- President 2003-2007

MASCC (Member Palliative Care, Geriatric and Neutropenia Study Groups)

Swiss Society for Medical Oncology (SGMO) (Swiss National Representative for ESMO 2012-2014)

Swiss Society for Palliative Care (palliative.ch)

palliative aargau (Co-President since 2013)

Swiss Association of Internal Medicine

Swiss Medical Association

Past Clinical and Research Positions, Postgraduate Training

2003: Specialist / Consultant in Medical Oncology and Internal Medicine, Lausanne, CH

2000 - 2002: Chef de Clinique, Medical Oncology, University Hospital Lausanne, CH

1998 - 2000: Clinical Scientist and Specialist Registrar in Medical Oncology (Dr. T. Perren, Dr. R. Banks, Prof. P. Selby), Academic Unit Clinical Trials

Coordinator (Prof. P. Selby), ICRF Cancer Medicine Research Unit, St. James's University Hospital, Leeds, UK
 Radiotherapy, Cookridge Hospital, Cookridge, UK
 Locum Consultant Medical Oncologist, Airedale General Hospital, UK
 1998: Trainee in Haematology, University Hospital Basle, CH
 1996 - 1997: Registrar in Medical Oncology, Department of Medicine, The Royal Hospital, Sutton, UK (Dr D. Cunningham)
 1996: Senior House Officer, Department of Medicine, The Royal Marsden Hospital, Sutton, UK (Dr. D. Cunningham)
 1995: Senior House Officer, Department of Medical Oncology, St Bartholomew's Hospital, London, UK (Prof. T.A. Lister)
 1992- 1995: Trainee in Internal Medicine, University Hospital Basle, CH (including subspecialty rotations of 6 months each in Medical Oncology, Hematology, Intensive Care and Medical Emergency Department)
 1990- 1992: Postgraduate Fellow in Molecular Biology awarded by the Department of Physiology, University of Manitoba, Winnipeg, Canada (Prof. H. G. Friesen)

Clinical Research, Teaching

- **Author of clinical trials** in Hodgkin's disease, breast, colorectal, oesophageal, bladder cancer and melanoma
- Collaborator in **clinical trials groups** in Switzerland (SAKK) and abroad (IBCSG, EORTC, UK).
- Co-founder and 2004-2007 president of the **Flims Alumni Club**, an interdisciplinary organization of young cancer specialists and researchers focused among other goals on clinical trial methodology.
- Co-organiser of various symposia within ESMO, ESTRO, EACR, ECCO.
- Visiting Professor, Faculty of Medicine, University of Belgrade, Serbia
- Faculty member of the European Society of Medical Oncology (ESMO)
- Core Faculty Member European School of Oncology (ESO).

Publications

1. **Popescu RA** and Popescu G, Assessment of symptoms and needs. ESMO Handbook of Supportive and Palliative Care. Bosnjak S and Wood J Eds. 2022, in print
2. **Popescu RA**, Roila F, Arends J, Metro G, Lustberg M. Supportive Care: Low Cost, High Value. Am Soc Clin Oncol Educ Book 2021 Mar;41:1-11. doi: 10.1200/EDBK_320041.
3. Schmalz O, Jacob C, Ammann J, Liss B, Iivanainen S, Kammermann M, Koivunen J, Klein A, **Popescu RA**. Digital Monitoring and Management of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Treated With Cancer Immunotherapy and Its Impact on Quality of Clinical Care: Interview and Survey Study Among Health Care Professionals and Patients. J Med Internet Res 2020;22(12):e18655. DOI: [10.2196/18655](https://doi.org/10.2196/18655)
4. Rothschild SI, Betticher D, Zenhäusern R, Anchisi S, von Moos R, Pless M, Moosmann P, **Popescu RA**, Calderoni A, Dressler M, Rauch D, Pederiva S, Woelky R, Papet C, Bühler V, Borner M. Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study. Cancer Chemother Pharmacol. 2019 Oct;84(4):881-889. doi:10.1007/s00280-019-03927-x.
5. Selby P, **Popescu R**, Lawler M, Butcher H, Costa A. The Value and Future Developments of Multidisciplinary Team Cancer Care. Am Soc Clin Oncol Educ Book. 2019 Jan;39:332-340. doi: 10.1200/EDBK_236857.
6. Vrdoljak E, Bodoky G, Jassem J, **Popescu R**, Pirker R, Čufer T, Bešlija S, Eniu A, Todorović V, Kopečková K, Kurteva G, Tomašević Z, Sallaku A, Smichkoska S, Bajić Ž, Sikic B. Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe. Oncologist. 2019 Jan;24(1):e30-e37. doi: 10.1634/theoncologist.2018-0093.
7. Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM; SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018 Jul 12;379(2):122-137. doi: 10.1056/NEJMoa1803164.

8. Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di Leo A, Regan MM, Goldhirsch A, SOLE Investigators Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol.* 2018 Jan;19(1):127-138. doi: 10.1016/S1470-2045(17)30715-5
9. Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Cicenienne A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial *Lancet Oncol.* 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9
10. Stenner F, Rothschild SI, Betticher D, Caspar C, Morant R, **Popescu R**, Rauch D, Huber U, Zenhäusern R, Rentsch C, Cathomas R Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry *Clin Genitourin Cancer.* 2017 Aug 24. pii: S1558-7673(17)30244-6. doi: 10.1016/j.clgc.2017.08.003
11. Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. *Eur J Cancer.* 2017 Sep; 82:237-246. doi: 10.1016/j.ejca.2017.05.010
12. Ades F, Senterre C, Zardavas D, de Azambuja E, **Popescu R**, Piccart M. Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA. *PLoS One.* 2017 Mar 14;12(3):e0172351. doi: 10.1371/journal.pone.0172351. PubMed PMID: 28291814.
13. Eduard Vrdoljak, Gyorgy Bodoky, Jacek Jassem, **Razvan A. Popescu**, Jozef Mardiak, Robert Pirker, Tanja Čufer, Semir Bešlija, Alexandru Eniu, Vladimir Todorović, Kateřina Kubáčková, Galia Kurteva, Zorica Tomašević, Agim Sallaku, Snezhana Smichkoska, Žarko Bajić, Branimir I. Šikić Cancer control in Central and Eastern Europe - current situation and recommendations for improvement *The Oncologist* 2016 Jul 8. pii: theoncologist.2016-0137
14. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, AmosC, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh, O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R,

- Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. *Lancet*. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21. PubMed PMID: 26719232; PubMed Central PMCID: PMC4800035.
15. Saad F, Fizazi K, Jinga V, Efsthathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R; ELM-PC 4 investigators. Orteronel plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. *Lancet Oncol*. 2015 Mar;16(3):338-48. doi: 10.1016/S1470-2045(15)70027-6. Epub 2015 Feb 18. PubMed PMID: 25701170.
 16. Koeberle D, Betticher DC, von Moos R, Dietrich D, Brauchli P, Baertschi D, Matter K, Winterhalder R, Borner M, Anchisi S, Moosmann P, Kollar A, Saletti P, Roth A, Frueh M, Kueng M, **Popescu RA**, Schacher S, Hess V, Herrmann R. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). *Ann Oncol*. 2015 Apr;26(4):709-14. doi: 10.1093/annonc/mdv011. Epub 2015 Jan 20. PubMed PMID: 25605741.
 17. Ades F, Zardavas D, Senterre C, de Azambuja E, Eniu A, **Popescu R**, Piccart M, Parent F. Hurdles and delays in access to anti-cancer drugs in Europe. *Ecancermedicalscience*. 2014 Nov 17;8:482. doi: 10.3332/ecancer.2014.482. eCollection 2014. Review. PubMed PMID: 25525460; PubMed Central PMCID: PMC4263523.
 18. Adjuvant ovarian suppression in premenopausal breast cancer. Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE Jr, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD; SOFT Investigators; International Breast Cancer Study Group. Adjuvant ovarian suppression in premenopausal breast cancer. *N Engl J Med*. 2015 Jan 29;372(5):436-46. doi: 10.1056/NEJMoa1412379. Epub 2014 Dec 11. PMID: 25495490
 19. Ades F, Senterre C, Zardavas D, de Azambuja E, **Popescu R**, Parent F, Piccart M. An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab case. *Eur J Cancer*. 2014 Dec;50(18):3089-97. doi: 10.1016/j.ejca.2014.09.011. Epub 2014 Oct 19. PubMed PMID: 25446375.
 20. **Popescu R**, Ciardiello F, Stahel R; ESMO Executive Board. Reply to the letter to the editor 'Still a long way to go to achieve multidisciplinary for the benefit of patients: commentary on the ESMO position paper' by Valentini et al. *Ann Oncol*. 2014 Sep;25(9):1865. doi: 10.1093/annonc/mdu246. Epub 2014 Jul 15. PubMed PMID: 25028706.
 21. Ciardiello F, Arnold D, Casali PG, Cervantes A, Douillard JY, Eggermont A, Eniu A, McGregor K, Peters S, Piccart M, **Popescu R**, Van Cutsem E, Zielinski C, Stahel R. Delivering precision medicine in oncology today and in future-the promise and

challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). *Ann Oncol.* 2014 Sep;25(9):1673-8. doi: 10.1093/annonc/mdu217. Epub 2014 Jun 20. PubMed PMID: 24950979.

22. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribí K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators; International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. *N Engl J Med.* 2014 Jul 10;371(2):107-18. doi: 10.1056/NEJMoa1404037. Epub 2014 Jun 1. PubMed PMID:24881463; PubMed Central PMCID: PMC4175521.
23. **Popescu RA**, Schäfer R, Califano R, Eckert R, Coleman R, Douillard JY, Cervantes A, Casali PG, Sessa C, Van Cutsem E, de Vries E, Pavlidis N, Fumasoli K, Wörmann B, Samonigg H, Cascinu S, Cruz Hernández JJ, Howard AJ, Ciardiello F, Stahel RA, Piccart M. The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). *Ann Oncol.* 2014 Jan;25(1):9-15. doi: 10.1093/annonc/mdt522. Epub 2013 Dec 13. Erratum in: *Ann Oncol.* 2014 Apr;25(4):916. PubMed PMID: 24335854.
24. Ades F, Senterre C, de Azambuja E, Sullivan R, **Popescu R**, Parent F, Piccart M. Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states. *Ann Oncol.* 2013 Nov;24(11):2897-902. doi: 10.1093/annonc/mdt352. Epub 2013 Sep 28. PubMed PMID: 24078620.
25. Kubicka S, Greil R, André T, Bennouna J, Sastre J, Van Cutsem E, von Moos R, Osterlund P, Reyes-Rivera I, Müller T, Makrutzki M, Arnold D; ML18147 study investigators including AIO, GERCOR, FFCD, UNICANCER GI, TTD, BGDO, GEMCAD, and AGMT groups. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. *Ann Oncol.* 2013 Sep;24(9):2342-9. doi: 10.1093/annonc/mdt231. Epub 2013 Jul 12. PubMed PMID: 23852309.
26. Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. *Lancet Oncol.* 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16. PubMed PMID: 23168366.
27. James ND, Sydes MR, Mason MD, Clarke NW, Anderson J, Dearnaley DP, Dwyer J, Jovic G, Ritchie AW, Russell JM, Sanders K, Thalmann GN, Bertelli G, Birtle AJ, O'Sullivan JM, Protheroe A, Sheehan D, Srihari N, Parmar MK; STAMPEDE investigators. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. *Lancet Oncol.* 2012 May;13(5):549-58. doi: 10.1016/S1470-2045(12)70088-8. Epub 2012 Mar 26. Erratum in: *Lancet Oncol.* 2013 Jan;14(1):e5. PubMed PMID: 22452894; PubMed Central PMCID: PMC3398767.

28. Smith IE, Pierga JY, Biganzoli L, Cortés-Funes H, Thomssen C, Pivot X, Fabi A, Xu B, Stroyakovskiy D, Franke FA, Kaufman B, Mainwaring P, Pienkowski T, De Valk B, Kwong A, González-Trujillo JL, Koza I, Petrakova K, Pereira D, Pritchard KI; ATHENA Study Group. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. *Ann Oncol.* 2011 Mar;22(3):595-602. doi: 10.1093/annonc/mdq430. Epub 2010 Sep 5. PubMed PMID: 20819780.
29. Pavlidis N, Gatzemeier W, **Popescu R**, Stahel R, Pinedo H, Cavalli F, Costa A The Masterclass of the European School of Oncology: the 'key educational event' of the school. *Eur J Cancer.* 2010 Aug;46(12):2159-65. doi: 10.1016/j.ejca.2010.06.006. Epub 2010 Jul 6. PubMed PMID: 20609578.
30. von Moos R, Roth A, Ruhstaller T, Widmer L, Uhlmann C, Cathomas R, Köberle D, Simcock M, Lanz D, **Popescu R**. Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03). *Onkologie.* 2010;33(6):295-9. doi: 10.1159/000313598. Epub 2010 May 14. PubMed PMID: 20523092.
31. Ruhstaller T, Templeton A, Ribi K, Schuller JC, Borner M, Thierstein S, von Moos R, Pederiva S, Lohri A, Lombriser N, von Briel C, Koeberle D, **Popescu R**. Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02). *Onkologie.* 2010;33(5):222-8. doi: 10.1159/000305094. Epub 2010 Apr 9. PubMed PMID: 20502056.
32. **Popescu R**, von Rohr A, Piguet D, Irlé C, Giger M, Brunner R, Ahnesorg P, Zappa F. Rapid anaemia control with epoetin: results of a Swiss survey on treatment of chemotherapy-induced anaemia. *Acta Haematol.* 2010;123(2):129-34. doi: 10.1159/000276978. Epub 2010 Jan 21. PubMed PMID: 20145388.
33. Ruhstaller T, Widmer L, Schuller JC, Roth A, Hess V, Mingrone W, von Moos R, Borner M, Pestalozzi BC, Balmermajno S, Köberle D, Terraciano L, Schnider A, Bodis S, **Popescu R**; Swiss Group for Clinical Cancer Research (SAKK). Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). *Ann Oncol.* 2009 Sep;20(9):1522-8. doi: 10.1093/annonc/mdp045. Epub 2009 May 22. PubMed PMID: 19465425.
34. Peters S, Voelter V, Zografos L, Pampallona S, **Popescu R**, Gillet M, Bosshard W, Fiorentini G, Lotem M, Weitzen R, Keilholz U, Humblet Y, Piperno-Neumann S, Stupp R, Leyvraz S. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. *Ann Oncol.* 2006 Apr;17(4):578-83. Epub 2006 Feb 9. PubMed PMID: 16469752.
35. Borner MM, Bernhard J, Dietrich D, **Popescu R**, Wernli M, Saletti P, Rauch D, Herrmann R, Koeberle D, Honegger H, Brauchli P, Lanz D, Roth AD; Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. *Ann Oncol.* 2005 Feb;16(2):282-8. PubMed PMID: 15668285.
36. Craven RA, Stanley AJ, Hanrahan S, Totty N, Jackson DP, **Popescu R**, Taylor A, Frey J, Selby PJ, Patel PM, Banks RE. Identification of proteins regulated by

interferon-alpha in resistant and sensitive malignant melanoma cell lines. *Proteomics*. 2004 Dec;4(12):3998-4009. PubMed PMID: 15449380.

37. Givel JC, Aellen S, Moubayed H, Michetti P, Dorta G, **Popescu R**. [Colorectal cancer: curative treatment and surveillance]. *Rev Med Suisse Romande*. 2002 Sep;122(9):417-9. French. PubMed PMID: 12422469.
38. Moubayed H, **Popescu R**, Aellen S, Givel JC, Michetti P, Dorta G. [Detection and prevention of colorectal cancer]. *Rev Med Suisse Romande*. 2002 Sep;122(9):413-6. French. PubMed PMID: 12422468.
39. Foran JM, Gupta RK, Cunningham D, **Popescu RA**, Goldstone AH, Sweetenham JW, Pettengell R, Johnson PW, Bessell E, Hancock B, Summers K, Hughes J, Rohatiner AZ, Lister TA. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. *Br J Haematol*. 2000 Apr;109(1):81-8. PubMed PMID: 10848785.
40. Foran JM, Rohatiner AZ, Cunningham D, **Popescu RA**, Solal-Celigny P, Ghielmini M, Coiffier B, Johnson PW, Gisselbrecht C, Reyes F, Radford JA, Bessell EM, Souleau B, Benzohra A, Lister TA. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. *J Clin Oncol*. 2000 Jan;18(2):317-24. Erratum in: *J Clin Oncol* 2000 May;18(9):2006. PubMed PMID: 10637245.
41. **Popescu RA**, Norman A, Ross PJ, Parikh B, Cunningham D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. *J Clin Oncol*. 1999 Aug;17(8):2412-8. PubMed PMID: 10561304.
42. **Popescu RA**, Wotherspoon AC, Cunningham D, Norman A, Prendiville J, Hill ME. Surgery plus chemotherapy or chemotherapy alone for primary intermediate- and high-grade gastric non-Hodgkin's lymphoma: the Royal Marsden Hospital experience. *Eur J Cancer*. 1999 Jun;35(6):928-34. PubMed PMID: 10533473.
43. **Popescu RA**, Lohri A, de Kant E, Thiede C, Reuter J, Herrmann R, Rochlitz CF. bcl-2 expression is reciprocal to p53 and c-myc expression in metastatic human colorectal cancer. *Eur J Cancer*. 1998 Jul;34(8):1268-73. PubMed PMID: 9849490.
44. **Popescu RA**, Wotherspoon AC, Cunningham D. Local recurrence of a primary pancreatic lymphoma 18 years after complete remission. *Hematol Oncol*. 1998 Mar;16(1):29-32. PubMed PMID: 9821409.
45. **Popescu RA**, Wotherspoon AC, Cunningham D. High-dose chemotherapy and autologous transplantation in lymphomatous polyposis in second remission: three case reports and literature review. *Bone Marrow Transplant*. 1998 Jul;22(1):103-6. PubMed PMID: 9678804.
46. Ross P, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, Prendiville J, Watson M, Massey A, **Popescu R**, Oates J. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. *Ann Oncol*. 1997 Oct;8(10):995-1001. PubMed PMID: 9402173.
47. **Popescu RA**, Cunningham D. Prevention of nausea and vomiting in repeat courses, in Dicato M (ed): *Medical Management of Cancer Treatment Induced Emesis*, pp 131-148. London, Martin Dunitz, 1997.

48. **Popescu RA**, Cunningham D. Chemotherapy for advanced pancreatic cancer—some light at the end of the tunnel? *Ann Oncol.* 1997 May;8(5):415-6. PubMed PMID: 9233516.
49. Waters JS, Ross PJ, **Popescu RA**, Cunningham D. New approaches to the treatment of gastro-intestinal cancer. *Digestion.* 1997;58(6):508-19. Review. PubMed PMID: 9438595.
50. Kasper S, **Popescu RA**, Torsello A, Vrontakis ME, Ikejiani C, Friesen HG. Tissue-specific regulation of vasoactive intestinal peptide messenger ribonucleic acid levels by estrogen in the rat. *Endocrinology.* 1992 Apr;130(4):1796-801. PubMed PMID: 1547709.